The Dutch Parkinson and Cognition Study (DUPARC): A prospective study on cognitive pathology in de novo Parkinson*s disease

The Dutch Parkinson and Cognition Study (DUPARC): A prospective study on cognitive pathology in de novo Parkinson*s disease - The Dutch Parkinson and Cognition Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50521

Enrollment

455

Registered

2017-05-11

Start date

2017-10-09

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Parkinson's disease

Interventions

None listed

Eligibility

Age

65 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosis Parkinson*s disease - Disease duration

Exclusion criteria

Exclusion criteria: All subjects: - The refusal to be informed about an unforeseen clinical finding, Exclusion from PET:, - Pregnant or breast feeding women, Exclusion from MRI scan:, - MR incompatible implants in the body (e.g. prosthesis, pacemakers, implanted heart valves). - Any risk of having metal particles in the eyes due to manual work without proper eye protections - Tattoos containing red pigments that form a safety risk

Design outcomes

Primary

Measure	Time frame
The primary endpoints will be the change in FEOBV activity and the change in cognitive functioning between baseline and 3 years of follow-up. Cognitive functioning is measured by an extensive neuropsychological assessment, covering all cognitive domains.	—

Secondary

Measure	Time frame
The secondary endpoints will be: - F-DOPA uptake as a measure of dopaminergic innervation. - Retinal evaluation using OCT technology - Functional connectivity using fMRI resting state - Neuropsychological assessment, including questionnaires - Systemic inflammation - Screening Array (GSA-MD) and/or whole-gene sequencing of the GBA1 gene. - GCase activity	—

Countries

Netherlands

Outcome results